Evidence map›Paper›PMID 39787187›Full record

ArticlePloS one2025

Household transmission of SARS-CoV-2 in five US jurisdictions: Comparison of Delta and Omicron variants.

Julia M Baker, Jasmine Y Nakayama, Michelle O'Hegarty, Andrea McGowan, Richard A Teran, Stephen M Bart, Lynn E Sosa, Jessica Brockmeyer, Kayla English, Katie Mosack and 11 more

Abstract readComparative Study
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Julia M BakerCOVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID 0000-0001-7872-316X
Jasmine Y NakayamaCOVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Michelle O'HegartyCOVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Andrea McGowanCOVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Richard A TeranEpidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Stephen M BartEpidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Lynn E SosaConnecticut Department of Public Health, Hartford, Connecticut, United States of America.
Jessica BrockmeyerConnecticut Department of Public Health, Hartford, Connecticut, United States of America.
Kayla EnglishChicago Department of Public Health, Chicago, Illinois, United States of America.
Katie MosackMilwaukee Health Department, Milwaukee, Wisconsin, United States of America.
Sanjib BhattacharyyaMilwaukee Health Department, Milwaukee, Wisconsin, United States of America.
Manjeet KhubbarMilwaukee Health Department, Milwaukee, Wisconsin, United States of America.
Nicole R YerkesUtah Department of Health and Human Services, Salt Lake City, Utah, United States of America.
Brooke CamposUtah Department of Health and Human Services, Salt Lake City, Utah, United States of America.
Alina PaegleUtah Department of Health and Human Services, Salt Lake City, Utah, United States of America.
John McGeeUtah Department of Health and Human Services, Salt Lake City, Utah, United States of America.
Robert HerreraUtah Department of Health and Human Services, Salt Lake City, Utah, United States of America.
Marcia PearlowitzMaryland Department of Health, Baltimore, Maryland, United States of America.
Thelonious W WilliamsMaryland Department of Health, Baltimore, Maryland, United States of America.
Hannah L KirkingCOVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Jacqueline E TateCOVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Households are a significant source of SARS-CoV-2 transmission, even during periods of low community-level spread. Comparing household transmission rates by SARS-CoV-2 variant may provide relevant information about current risks and prevention strategies. This investigation aimed to estimate differences in household transmission risk comparing the SARS-CoV-2 Delta and Omicron variants using data from contact tracing and interviews conducted from November 2021 through February 2022 in five U.S. public health jurisdictions (City of Chicago, Illinois; State of Connecticut; City of Milwaukee, Wisconsin; State of Maryland; and State of Utah). Generalized estimating equations were used to estimate attack rates and relative risks for index case and household contact characteristics. Data from 848 households, including 2,622 individuals (median household size = 3), were analyzed. Overall transmission risk was similar in households with Omicron (attack rate = 47.0%) compared to Delta variant (attack rate = 48.0%) circulation. In the multivariable model, a pattern of increased transmission risk was observed with increased time since a household contact's last COVID-19 vaccine dose in Delta households, although confidence intervals overlapped (0-3 months relative risk = 0.8, confidence interval: 0.5-1.2; 4-7 months relative risk = 1.3, 0.9-1.8; ≥8 months relative risk = 1.2, 0.7-1.8); no pattern was observed in Omicron households. Risk for household contacts of symptomatic index cases was twice that of household contacts of asymptomatic index cases (relative risk = 2.0, 95% confidence interval: 1.4-2.9), emphasizing the importance of symptom status, regardless of variant. Uniquely, this study adjusted risk estimates for several index case and household contact characteristics and demonstrates that few characteristics strongly dictate risk, likely reflecting the complexity of the biological and social factors which combine to impact SARS-CoV-2 transmission.

Indexed as

Contact TracingCOVID-19Family CharacteristicsSARS-CoV-2AdolescentAdultAgedChildChild, PreschoolFemaleHumansInfantMaleMiddle AgedUnited StatesYoung Adult

Identifiers

PMID39787187
PMCPMC11717262

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.